FVFelipe Nathanael Coelho Vaz

Felipe Nathanael Coelho Vaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Felipe Nathanael Coelho Vaz has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EFEITOS DA ADMINISTRAÇÃO SUBCRÔNICA DE Baccharis dracunculifolia (BR 10 2012 020540-8 A2) EM MODELO ANIMAL DE DIABETES TIPO I

    by Nilane Françoise Patel, Bruno Moreira Soares, Daniele Fernanda Renzi, Andressa Razera Pezoti, Jéssica Wouk, Carlos Ricardo Maneck Malfatti, Luiz Augusto Silva, Vanusa Karini Savighago Savighago, Felipe Nathanael Coelho Vaz

    O Diabetes mellitus (DM) destaca-se como um problema de saúde pública mundial. Diante disso, várias espécies de plantas vêm sendo utilizadas para tratar e/ou combater os sintomas do DM. O objetivo deste estudo foi avaliar os efeitos da ingestão subcrônica do extrato de Baccharis dracunculifolia, em modelo animal de DM. Foram utilizados 56 ratos machos da linhagem Wistar, tratados por 28 dias. O modelo de DM tipo I foi induzido pela administração de 60 mg/kg de estreptozotocina. O grupo CB demonstrou 14,8% (p<0.05) menor consumo de ração que o grupo DB200. Quanto à ingestão hídrica, o grupo CDT teve maior ingesta (44,1%; p<0.05) com relação aos grupos tratados. Na glicemia capilar em jejum e pós-prandial, os grupos tratados apresentaram redução de 54,3% a 63,4% ao jejum e 37,9% a 45% no pós-prandial. Conclui-se que o extrato metanólico de B. dracunculifolia reduziu os níveis glicêmicos em ratos diabéticos tipo I.

  • Open Access

    Polypharmacy in Alzheimer's disease patients in Brazil: Guidance for pharmaceutical assistance

    by Felipe Nathanael Coelho Vaz, Luana Bortoluzzi Trombim, Guilherme Barroso L. de Freitas, Maria Vaitsa Loch Haskel, Giovana dos Santos, Jéssica Wouk, Dayanna Hartmann Cambruzzi Mendes, Barbara Luisa Fermino, Flávia Ivanski, Juliana Sartori Bonini

    Background: Elderly patients frequently have concomitant diseases, triggering the necessity of utilizing several different medications, which can cause adverse events associated with therapy, called polypharmacy. This study aimed to evaluate the main concomitant diseases with Alzheimer's disease (AD) and discuss possible interactions between drugs utilized to treat dementia and its comorbidities, and indicate safe medicines for patients with AD. Methods: 41 individuals with AD who withdraw medicines for dementia from the Brazilian public health system (SUS) participated in this study. Data collection was performed using three questionnaires: 1) Clinical Dementia Rating, to verify disease stage; 2) Mini–mental state examination, to measure cognitive impairment; and 3) Sociodemographic analysis, to evaluate concomitant diseases, utilized drugs, drug-drug interactions, among other demographic variables. Statistical analyses were performed using SPSS and data was presented as relative frequency. Results: The results of this study showed that the most frequent concomitant diseases with AD are: systemic arterial hypertension, depression, diabetes mellitus, and hypercholesterolemia. Polypharmacy was observed in 95.12% of patients. The pharmacologic classes that presented interactions with AD medications were anxiolytics, antidepressants, antipsychotics, antihypertensives, and antidiabetics. Conclusion: In the present study, polypharmacy in patients with AD and other concomitant diseases has been characterized. The average number of drugs that these patients ingested was seven per day, and this leads to drug interactions, which are potentially damaging to the body. Consequently, we have tried to reduce these interactions, by suggesting drugs that are safer, for example furosemide instead of amlodipine to treat hypertension.